ClinicalTrials.gov
ClinicalTrials.gov Menu

A Genomic Approach for Clopidogrel in Caribbean Hispanics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03419325
Recruitment Status : Recruiting
First Posted : February 1, 2018
Last Update Posted : February 1, 2018
Sponsor:
Collaborators:
National Institute on Minority Health and Health Disparities (NIMHD)
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Jorge Duconge, University of Puerto Rico

Brief Summary:
Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with cardiovascular disease, particularly those undergoing heart catheterization and stroke. A substantial amount of medical evidence has proven that patients with stroke or heart diseases can benefit from this medicine. However, significant variability in such expected benefits has been found among individuals receiving Clopidogrel, with some patients not having the benefit of reduced complications and adverse cardiovascular events. Prior studies have demonstrated a significant association between certain variants on patient's genes (e.g., CYP2C19) and poor response to Clopidogrel and, therefore, major adverse cardiovascular events. Variation in other genes and other factors such as platelet activation, weight, diabetes mellitus (a medical condition that produces high blood sugar), concomitant use of other drugs and smoking status have also been proposed to be related with the same adverse outcomes. In this study the investigators would like to determine a possible association between these genes and the response to the medication among Caribbean Hispanic cardiovascular patients on Clopidogrel. In other population, it is known that patients with certain genetic variants have lower or magnified response to this medication when compared to those individuals taking the same dose and not carrying the genetic variations. However, a fundamental gap remains in understanding whether the genomic diversity of Caribbean Hispanics accounts for the observed high inter-individual variability of clinical outcomes to preventive dual antiplatelet therapy (DAPT) with Clopidogrel.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease (CVD) Stroke Acute Coronary Syndrome Peripheral Arterial Disease Coronary Artery Disease Myocardial Infarction Genetic: CYP2C19 test Diagnostic Test: P2RY12 assay Not Applicable

Detailed Description:

Despite the substantial work in cardiovascular pharmacogenomics published over the past decade, a fundamental gap remains in understanding whether the genomic diversity of Caribbean Hispanics accounts for high inter-individual variability of clinical outcomes to preventive dual antiplatelet therapy (DAPT) with Clopidogrel. Caribbean Hispanics are disproportionately affected by cardio-metabolic disorders, but with a limited expectation of benefits from existing genomic-based algorithms. The investigators will focus on Clopidogrel to develop urgently-needed genomic-driven prescription guidelines for this population. To this purpose, the investigators propose to perform the first ever genome-wide association study (GWAS) of a pharmacogenetically actionable prescription drug in Caribbean Hispanics. This proposal will also take a novel approach to definitively assess the admixture component and is also highly practical for the development of a clinical decision support (CDS) tool. The investigators will implement a treatment algorithm to guide DAPT in Caribbean Hispanics and will create a repository of genomic DNAs and fully annotated clinical and genomic dataset from Caribbean Hispanics with cardiovascular diseases. The investigators will test the following hypothesis:

There are unknown genetic variants that uniquely contribute to Clopidogrel responsiveness in Caribbean Hispanics to such extent that a developed CDS tool that incorporates personal ethno-specific genotypes and ex vivo pharmacodynamics (PD) testing will help enable more precise recommendations for optimizing medical outcomes to antiplatelet therapy in this population. This hypothesis will be tested with the following specific aims:

1) To conduct a Genome-Wide Association Study (GWAS) of residual on-treatment platelet reactivity in Clopidogrel-treated Caribbean Hispanic patients of Puerto Rico. 2) To implement a treatment algorithm based on ex vivo PD and genetic test results to guide DAPT in Caribbean Hispanics. 3) To create a repository of biological specimens and fully annotated clinical and genomic dataset (relevant genotypes and phenotypes) from Caribbean Hispanics with cardiovascular diseases.

The study will be conducted over 5 years in 1,000 cardiovascular patients treated with Clopidogrel for secondary prevention of thromboembolic events. It is expected that this study advances the adoption of a Precision Medicine (PM) paradigm for the benefit of Hispanic patients. The richer genetic variance in Latinos is likely to contribute substantially to variability in response to drug treatments, a component that will be missed by traditional studies in homogeneous populations. This addressable oversight is of great concern, since it will tend to exacerbate the healthcare disparity already experienced by Hispanic populations in the US. Hispanics have been largely excluded from Precision Medicine initiatives, which increase dramatically the disparities in translating benefits from new findings in pharmacogenomics to this medically underserved population, exacerbating the existing inequity in healthcare services. Accordingly, the proposed research will expand current understanding on the pharmacogenomics of Clopidogrel. Advancing knowledge in the under-investigated area of pharmacogenetics in minority populations will generate results that apply to personalize DAPT in the wider population as it moves, inevitably, toward increasing heterogeneity through admixed genomes.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: After being consented, patients will undergo rapid ex vivo platelet functional testing (i.e., residual platelet reactivity units, PRU, measured using the VerifyNow P2R12 assay for Clopidogrel response) and CYP2C19 genotyping. Patients will then be categorized into 4 groups based on tests results: 1) high on-treatment platelet reactivity (HTPR)/ CYP2C19 loss-of-function (LOF) alleles (i.e., presence of both HTPR and CYP2C19 LOF alleles); 2) HTPR/No-LOF (presence of HTPR, but no CYP2C19 LOF allele); 3) No-HTPR/LOF (presence of a CYP2C19 LOF allele, but no HTPR); 4) No-HTPR/No-LOF (absence of both HTPR and CYP2C19 LOF alleles).
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Adopting a Precision Medicine Paradigm in Puerto Rico: Leveraging Ancestral Diversity to Identify Predictors of Clopidogrel Response in Caribbean Hispanics
Actual Study Start Date : January 17, 2018
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HTPR/LOF

Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:

An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.

Genetic: CYP2C19 test
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Diagnostic Test: P2RY12 assay
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Experimental: HTPR/no-LOF

Presence of HTPR, but no CYP2C19 LOF allele found:

An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.

Genetic: CYP2C19 test
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Diagnostic Test: P2RY12 assay
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Experimental: no-HTPR/LOF

Presence of a CYP2C19 LOF allele, but no HTPR:

An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.

Genetic: CYP2C19 test
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Diagnostic Test: P2RY12 assay
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Experimental: No-HTPR/No-LOF

Absence of both HTPR and CYP2C19 LOF alleles:

Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.

Genetic: CYP2C19 test
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Diagnostic Test: P2RY12 assay
Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).




Primary Outcome Measures :
  1. Major adverse cardiovascular events (MACE) reductions [ Time Frame: six months after intervention ]
    MACE reductions will be the composite of all-cause death, MI (according to the universal definition), stroke or coronary revascularization.


Secondary Outcome Measures :
  1. number of patients with treatment-related cardiovascular (CV) death [ Time Frame: six months after intervention ]
    death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, stroke, CV procedures, CV hemorrhage and other CV causes.

  2. number of patients with treatment-related stent thrombosis [ Time Frame: six months after intervention ]
    definite or confirmed stent thrombosis as proposed by the Academic Research Consortium (ARC): i.e., symptoms suggestive of an acute coronary syndrome and angiographic or pathologic confirmation of stent thrombosis.

  3. Bleeding [ Time Frame: six months after intervention ]
    as defined by Bleeding Academic Research Consortium (BARC) criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Caribbean Hispanics (Puerto Ricans, Dominicans or Cubans) residing in Puerto Rico, whose parents are also of Hispanic origin
  • Both genders (Males/Females)
  • Age ≥21
  • Receiving Clopidogrel for therapeutic indications.
  • No clinically active hepatic abnormality
  • The ability to understand the requirements of the study
  • The ability to comply with study procedures and protocol
  • A female patient is eligible to enter the study if she is of child-bearing potential and not pregnant or nursing, or not of child-bearing potential

Exclusion Criteria:

  • Non-Hispanic patients (race/ethnicity is self-reported by the patients)
  • Currently enrolled in another active research protocols at the participating institutions
  • BUN >30
  • Creatinine >2.0 mg/dL
  • Platelet count <100,000/mm3
  • Nasogastric or enteral feedings
  • Acute illness (e.g., sepsis, infection, anemia)
  • HIV/AIDS, Hepatitis B patients
  • Alcoholism and drug abuse
  • Patients with any cognitive and mental health impairment
  • Sickle cell patients
  • Active malignancy
  • Patients taking another antiplatelet

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03419325


Contacts
Contact: Jorge Duconge, PhD (787) 758-2525 ext 5312 jorge.duconge@upr.edu
Contact: Kyle Melin, PharmD (787) 758-2525 ext 3711 kyle.melin@upr.edu

Locations
Puerto Rico
University Hospital at Carolina Recruiting
Carolina, Puerto Rico, 00984
Contact: Angel Lopez-Candales, MD       candales33@gmail.com   
Cardiovascular Hospital of Puerto Rico and the Caribbean Recruiting
San Juan, Puerto Rico, 00926
Contact: Dagmar F Hernandez-Suarez, MD       dagmar.hernandez@upr.edu   
Sponsors and Collaborators
University of Puerto Rico
National Institute on Minority Health and Health Disparities (NIMHD)
Icahn School of Medicine at Mount Sinai
Investigators
Principal Investigator: Jorge Duconge, PhD University of Puerto Rico

Responsible Party: Jorge Duconge, Proffesor, PhD, University of Puerto Rico
ClinicalTrials.gov Identifier: NCT03419325     History of Changes
Other Study ID Numbers: A4070417
2U54MD007600-31 ( U.S. NIH Grant/Contract )
First Posted: February 1, 2018    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jorge Duconge, University of Puerto Rico:
percutaneous coronary interventions (PCI)
secondary stroke prevention
dual antiplatelet therapy (DAPT)

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Acute Coronary Syndrome
Heart Diseases
Infarction
Cardiovascular Diseases
Myocardial Ischemia
Myocardial Infarction
Peripheral Arterial Disease
Peripheral Vascular Diseases
Ischemia
Pathologic Processes
Necrosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Atherosclerosis
Clopidogrel
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs